Claims

1. Use of neurotrophin in the manufacture of a medicament for the treatment of hearing disorders, characterized in that the medicament is to be administered by intratympanic route.

2. The use according to claim 1, characterized in that said neurotrophin is selected from NGF, brain-derived neurotrophic factor (BDNF), neurotrophin 3 and neurotrophin 4, preferably NGF.

3. The use according to claims 1 or 2, characterized in that said disorders are selected from sudden deafness, blast-induced hearing loss, ototoxicity, ARHL (age related hearing loss) and noise damage.

4. The use according to any of the previous claims, characterized in that the medicament is to be administered by means of a composition further comprising at least a pharmaceutically acceptable excipient.

5. The use according to claim 4, characterized in that said pharmaceutically acceptable excipient is selected from hyaluronic acid, polyvinyl alcohol, glycerol, poly-lactic-co-glycolic acid and PEG400, preferably hyaluronic acid, polyvinyl alcohol or glycerol.

6. The use according to any of the previous claims, characterized in that said composition is a solution, a suspension, microparticles or a gel.

7. The use according to claim 6, wherein said microparticles are of PLGA.

8. The use according to any of the previous claims, characterized in that said composition is to be administered simultaneously, separately or sequentially in combination with a further active principle.

9. The use according to claim 8, characterized in that said further active principle is a steroid, selected from dexamethasone, methylprednisolone and prednisolone.

10. The use according to any of the previous claims, characterized in that said composition contains from 1 μg to 1.2 mg of NGF, preferably from 10 μg to 200 μg of NGF, more preferably from 2 μg to 20 μg of NGF.

11. The use according to claim 6, characterized in that said solution contains a concentration of NGF ranging from 1 μg/ml to 1.2 mg/ml, preferably from 10 μg/ml to 200 μg/ml, more preferably from 2 μg/ml to 20 μg/ml .

12. The use according to claim 6, characterized in that said suspension contains a concentration of NGF ranging from 1 μg/ml to 1.2 mg/ml, preferably from 10 μg/ml to 200 μg/ml, more preferably from 2 μg/ml to 20 μg/ml .

13. The use according to claim 6, characterized in that said microparticles contain a concentration of NGF ranging from 1 μg/ml to 1.2 mg/ml, preferably from 10 μg/ml to 200 μg/ml, more preferably from 2 μg/ml to 20 μg/ml .

14. The use according to any of the previous claims, characterized in that said neurotrophin is of murine or human origin or it is a human recombinant neurotrophin.

15. The use according to claim 14, characterized in that said neurotrophin is a NGF of murine or human origin or it is a human recombinant NGF.

16. The use according to any of the previous claims, characterized in that said composition is to be administered daily, preferably one or more time a day.